Navigation Links
INV102 Asthma Product Discussed at the European Respiratory Society
Date:9/22/2009

SAN FRANCISCO, Sept. 22 /PRNewswire/ -- A symposium was held last week at the European Respiratory Society's annual meeting in Vienna, Austria entitled "Beta-blockers may now be beneficial in asthma and COPD."

"It is remarkable how far Inverseon's asthma program has advanced in the past couple of years. We now have data from two clinical trials and evidence is accumulating that INV102 is showing pre-clinical activity with respect to each of the major hallmarks of asthma: airway hyperresponsiveness, inflammation, and mucous hypersecretion," stated Amie E. Franklin, PhD, of Inverseon.

"The symposium at an international respiratory conference demonstrated that the approach of using certain beta-blockers in asthmatics is gaining increasing scientific and clinical recognition," stated Richard A. Bond, scientific founder of Inverseon and Prof. of Pharmacology at the University of Houston.

"The presentations very much support the clinical development of our proprietary controlled-release oral formulation, INV102CR. We believe that INV102CR may provide an important steroid sparing treatment option in an oral dosage form," said William J. Garner, MD, Chairman of Inverseon.

About Inverseon, Inc.

Inverseon's product development programs target significant unmet medical needs and major market opportunities in chronic pulmonary diseases such as asthma, COPD and pulmonary hypertension. Inverseon was founded based on the original work of Prof. Richard Bond of the University of Houston. Professor Bond termed the effects "Paradoxical Pharmacology," based on the divergence of acute versus chronic effects of certain drugs in chronic diseases. For further information, please visit Inverseon's website at http://www.inverseon.com.

Forward-Looking Statement

This press release may contain forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events, or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.

    Contact:

    William J. Garner, MD
    1701 Jackson Street, 102
    San Francisco, CA 94109
    bill@inverseon.com
   http://www.inverseon.com
    (917) 653-0470

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Inverseon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Knocking the Wind Out of Asthmatics: Help from Hippocrates
2. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
3. New Study Funded By the National Institutes of Health (NIH) Finds Masimo SpCO(R) May Provide a Noninvasive Measure of Acute Asthma Severity in Children
4. SiliconSky GPS Designs First AGPS-Enabled Asthma Inhaler for Landmark Research Program
5. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
6. Inverseons Asthma Therapy Receives Notice of Allowance; Clinical Trial Highlighted in Lancet
7. MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor
8. Visualizing asthma-causing immune cells at work
9. New consensus on work-related asthma
10. Video: ASMANEX(R) TWISTHALER(R) 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance Treatment of Asthma in Children Ages 4 to 11
11. New Patient Satisfaction Study With budesonide/formoterol Combination Therapy and fluticasone/salmeterol Combination Therapy in Adults With Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... January 16, 2017 , ... Attagene , a Research ... U.S. Small Business Administration. The Tibbetts Award honors the Small Business Innovation ... and are considered the best of the best from the thousands of firms ...
(Date:1/13/2017)... Research and Markets has announced the addition ... Forecast to 2021" report to their offering. ... The biosimilars market is expected ... in 2016, at a CAGR of 26.3%. The ... type, and application. Factors such as rising incidence of various diseases, ...
(Date:1/13/2017)... ... January 13, 2017 , ... FireflySci, in response to ... three new solutions for measurements where traditional cuvette applications are not convenient. For ... an oddly-shaped sample that would not fit into a typical cuvette inside a ...
(Date:1/12/2017)... NE (PRWEB) , ... January 12, 2017 , ... ... hiring of Stephen Beck, who will work in the company’s Lincoln office as a ... chemical processes to design control systems for customers in the life science manufacturing and ...
Breaking Biology Technology:
(Date:1/13/2017)... 2017 Sandata Technologies, LLC, a leading ... industry, including Electronic Visit Verification™ (EVV™), announced today ... as Senior Vice President of Product Management. ... homecare experience to Sandata, where he will be ... align Sandata,s suite of solutions with the needs ...
(Date:1/12/2017)... , Jan. 12, 2017  Trovagene, Inc. (NASDAQ: ... DNA (ctDNA) technologies, today announced that it has signed ... and the Middle East ...  This milestone marks the first wave of international distribution ... urine and blood samples. The initial partners ...
(Date:1/12/2017)... YORK , Jan. 12, 2017  New research undertaken ... the office of the future.  1,000 participants were simply asked ... three months which we may consider standard issue.  Insights on ... of 2017 were also gathered from futurists and industry leaders ... Dr. James Canton .  Some of ...
Breaking Biology News(10 mins):